Tag: genomics
-
Enzyme Developer In-Licenses Synthetic Biology Technology
Novozymes A/S in Bagsvaerd, Denmark has agreed to license genetic engineering technology from MorphoSys AG in Martinsried, Germany for the development of industrial biotechnology products. The multi-year agreement provides Novozymes, a manufacturer of industrial enzymes, with a non-exclusive license to use MorphoSys’s Slonomics technology. Financial and more precise timetable details of the deal were not…
-
GE, Acorn Research to Partner on Molecular Cancer Testing
Clarient Inc., a division of GE Healthcare in Aliso Viejo, California, and ACORN Research in Memphis have agreed to collaborate on molecular testing of tumor samples to result in standardized molecular profiles that improve the link between testing and treatment. These processes, say the companies, can eventually improve cancer treatment and research by delivering targeted…
-
Video Game Players Add to Genetic Disease Understanding
Users of a Web-based video game developed by McGill University computer scientists in Montreal, have helped advance an understanding of the genetic basis of diseases such as Alzheimer’s, diabetes, and cancer over the past year. Jérôme Waldispuhl of the McGill School of Computer Science and collaborator Mathieu Blanchette released results today of the solutions collected…
-
Genome Institute to Fund Research on Rare Diseases, Medical Care
Funding announced by the National Human Genome Research Institute (NHGRI), part of National Institutes of Health, will support new research on rare inherited diseases, informatics tools, and use of genomic data in medical care delivery. The four-year, $416 million plan also continues funding for current initiatives on large-scale genomic sequencing production. NHGRI plans to award…
-
Trial Shows Safety of Engineered Gene Therapy
In an early-stage clinical trial, researchers at University of North Carolina in Chapel Hill have demonstrated the safety of creating a genetically-engineered virus to treat a form of muscular dystrophy. The findings of pharmacologist Jude Samulski (pictured left) and colleagues are reported online in the journal Molecular Therapy; paid subscription required. With gene therapy, a…
-
Patent Awarded for Synthetic Canine Antimicrobial Peptide
Kansas State University in Manhattan says a team of its researchers has received a U.S. patent for their discovery of a synthetic peptide that helps dogs better fight pathogens, such as bacteria, viruses and fungi. The patent, “Antimicrobial Cathelicidin Peptides” was awarded by the U.S. Patent and Trademark Office to K-State nutritionist Tonatiuh Melgarejo, immunophysiologist…
-
Contract Awarded for Atlantic Salmon Genome Sequencing
An international business and scientific consortium from salmon-producing countries has awarded a contract for the second phase of sequencing and analysis of the Atlantic salmon genome to the J. Craig Venter Institute (JCVI) in Rockville, Maryland. The International Cooperation to Sequence the Atlantic Salmon Genome (ICSASG) that awarded the contract is a partnership of five…
-
Genomics Testing Offered to Guide Cancer Treatments
Washington University in St. Louis, Missouri now provides a test for mutations in 28 genes associated with cancer to help determine the best treatment for cancer patients. Genes in the test are expected to cover a variety of different tumors, including those from blood, lymph, lung, brain, bladder, kidney, skin, stomach, prostate and breast cancers.…
-
Genetically Altered Algae Increases Biomass for Biofuels
An Iowa State University biologist has developed a process for genetically altering a strain of algae to increase its biomass content by up to 80 percent. This discovery, which can lead to enhanced production of biofuels from non-food sources, is available for licensing from the university’s technology transfer office. Martin Spalding (pictured right), leads a…
-
Diagnostics Developer Secures $100M Series C Financing
Biocartis, a diagnostic systems company in Lausanne, Switzerland says it completed raising €71 million (US$100 million) in series C equity funds, led by the company’s senior management and backed by current and new investors, as well as industrial collaborators. Series C financing is the third round of equity funding after start-up. Biocartis develops compact molecular…